Literature DB >> 10706586

Determination of the tissue sites responsible for the catabolism of large high density lipoprotein in the African green monkey.

K W Huggins1, E R Burleson, J K Sawyer, K Kelly, L L Rudel, J S Parks.   

Abstract

In vivo multicompartmental modeling of the turnover of HDL subfractions has suggested that HDL containing four molecules of apoA-I per particle and no other apolipoproteins (large LpA-I) are terminal particles in plasma. We hypothesized that these terminal particles were the end product of HDL metabolism and, as such, would be cleared preferentially by the liver. Thus, the purpose of this study was to determine: 1) the tissue sites of catabolism of large LpA-I in African green monkeys, and 2) whether saturated versus n;-6 polyunsaturated dietary fat affected tissue accumulation. Large LpA-I were isolated, without ultracentrifugation, by size exclusion and immunoaffinity chromatography and radiolabeled with either the residualizing compound, (125)I-labeled tyramine cellobiose (TC), or with (131)I. After injection into recipient animals, the plasma die-away of the radiolabels was followed for 12 or 24 h, after which the animals were killed and tissues were collected for determining radiolabel sites of catabolism. The plasma die-away of the (125)I-labeled TC-LpA-I and (131)I-labeled LpA-I doses was similar suggesting that the TC radiolabeling did not modify the metabolism of the large LpA-I dose. The liver, adrenal, kidney, and spleen had the greatest accumulation of large LpA-I degradation products on a per gram tissue basis. On a whole organ basis, the liver was the major site of large LpA-I degradation in both the 12-h (15.4 +/- 0.3% of injected dose) and 24-h (9.1 +/- 0.6% of injected dose) catabolic studies. The kidney, compared to the liver, had less uptake of large LpA-I radioactivity in either study (1.3 +/- 0.4% and 1.2 +/- 0.3% of injected dose). There was no apparent influence of dietary fat type on the tissue accumulation of large LpA-I. We conclude that the liver is the primary site of catabolism of large LpA-I in the African green monkey.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10706586

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  4 in total

1.  Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I.

Authors:  Jenelle M Timmins; Ji-Young Lee; Elena Boudyguina; Kimberly D Kluckman; Liam R Brunham; Anny Mulya; Abraham K Gebre; Jonathan M Coutinho; Perry L Colvin; Thomas L Smith; Michael R Hayden; Nobuyo Maeda; John S Parks
Journal:  J Clin Invest       Date:  2005-04-07       Impact factor: 14.808

2.  Targeted Deletion of Hepatocyte Abca1 Increases Plasma HDL (High-Density Lipoprotein) Reverse Cholesterol Transport via the LDL (Low-Density Lipoprotein) Receptor.

Authors:  Alexander C Bashore; Mingxia Liu; Chia-Chi C Key; Elena Boudyguina; Xianfeng Wang; Caitlin M Carroll; Janet K Sawyer; Adam E Mullick; Richard G Lee; Shannon L Macauley; John S Parks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-06-06       Impact factor: 8.311

3.  Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL.

Authors:  Anny Mulya; Ji-Young Lee; Abraham K Gebre; Elena Y Boudyguina; Soon-Kyu Chung; Thomas L Smith; Perry L Colvin; Xian-Cheng Jiang; John S Parks
Journal:  J Lipid Res       Date:  2008-06-25       Impact factor: 5.922

4.  Characterization of circulating APOL1 protein complexes in African Americans.

Authors:  Allison Weckerle; James A Snipes; Dongmei Cheng; Abraham K Gebre; Julie A Reisz; Mariana Murea; Gregory S Shelness; Gregory A Hawkins; Cristina M Furdui; Barry I Freedman; John S Parks; Lijun Ma
Journal:  J Lipid Res       Date:  2015-11-18       Impact factor: 5.922

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.